Aqemia

Aqemia is a pharmaceutical technology company that uses generative AI and deep quantum physics to discover and design new therapeutic molecules at scale. The company’s platform combines physics-based molecular modeling with AI-driven generative algorithms to screen and optimize small molecules, determine their physical properties, and identify therapeutic targets for specific diseases. By integrating deep physics with generative AI, Aqemia aims to advance drug discovery beyond the limits of conventional and AI-augmented approaches, enabling the identification of novel drug candidates with improved accuracy and speed. The company maintains offices in Paris and London, with a drug discovery pipeline advancing across multiple therapeutic areas. Founded in 2019 and headquartered in Paris, France, Aqemia has raised approximately $100.7 million in Series A funding. Investors include Elaia, Eurazeo, Bpifrance, Cathay Innovation, Wendel, and Gouv.fr. The company has approximately 86 employees and operates in the AI-based drug discovery and life sciences technology sector.